Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $90.00 target price on the biotechnology company’s stock. Chardan Capital’s target price suggests a potential upside of 11.80% from the stock’s current price. A […]